Pancreatic Ductal Adenocarcinoma Clinical Trials in St Louis, Missouri

7 studies are recruiting for pancreatic ductal adenocarcinoma in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

   This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   21 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04851119 on ClinicalTrials.gov

2. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University-School of Medicine /ID# 257379, St Louis, Missouri

   Locations

   54 in total

   Run by

   AbbVie

   See if you can join NCT06084481 on ClinicalTrials.gov

3. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

   Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, St Louis, Missouri

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT06218914 on ClinicalTrials.gov

4. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University, St Louis, Missouri

   Locations

   82 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

5. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   Saint Louis University, St Louis, Missouri

   Locations

   11 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov

6. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

   Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   20 in total

   Run by

   Astellas Pharma Inc

   See if you can join NCT07094204 on ClinicalTrials.gov

7. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

   This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   14 in total

   Run by

   Verastem, Inc.

   See if you can join NCT07020221 on ClinicalTrials.gov